CalliSpheres载药微球经肝动脉化疗栓塞治疗大肝癌的近期疗效及安全性分析

目的探讨CalliSpheres载药微球经肝动脉化疗栓塞(DEB-TACE)治疗大肝癌的近期疗效及安全性。方法选取接受CalliSpheres DEB-TACE治疗的大肝癌患者作为观察组,并通过分层随机选取同期传统经肝动脉化疗栓塞(cTACE)治疗的大肝癌患者作为对照组,对比分析两组的近期疗效及安全性。结果共搜集60例大肝癌患者,观察组与对照组分别为30例。观察组1个月、3个月、6个月客观缓解率分别为73.3%、60%、46.7%,对照组1个月、3个月、6个月客观缓解率分别为40%、30%、16.7%;观察组1个月、3个月、6个月疾病控制率分别为90%、80%、70%,对照组1个月、3个月、6个月疾病控制率分别为63.3%、53.3%、43.3%。观察组不良反应发生率为90.0%,对照组不良反应发生率为96.7%。结论DEB-TACE治疗大肝癌的近期疗效优于cTACE,且安全可行,但结果仍需多中心、大样本的前瞻性随机对照研究加以验证。

Transcatheter Arterial Chemoembolization with CalliSpheres-Loaded Microspheres for Treatment of Large Primary Liver Cancer:Analysis of Short-Term Efficacy and Safety

Objective To investigate short-term efficacy and safety of CalliSpheres drug-eluding beads transcatheter arterial chemoembolization(DEB-TACE)for treatment of Iarge primary liver cancer.Methods The patients with Iarge primary liver cancer who accepted the treatment of DEB-TACE were enrolled as the observation group,and the patients with Iarge primary liver cancer who accepted the treatment of conventional transcatheter arterial chemoembolization(cTACE)in our hospital during the same period were randomly enrolled as the control group.Short-term efficacy and safety were contrasted in the two groups.Results The clinical data of 60 patients with Iarge primary liver cancer were collected in the study,with 30 patients in the observation group and controlgroup,respectively.The 1-month,3-month and 6-month objective response rates were 73.3%,60%and 46.7%respectively in the observation group,and 40%,30%and 16.7%respectively in the control group;The 1-month,3-month and 6-month disease control rates were 90%,80%and 70%respectively in the observation group,and 63.3%,53.3%and 43.3%respectively in the control group.The occurrence of adverse reactions was 90.0%in the observation group,and 96.7%in the control group.Conclusion DEB-TACE has a better short-term efficacy than cTACE in the treatment of large hepatocellular carcinoma,and it is safe and feasible.However,the results still need to be verified by a multicenter,large-scale prospective randomized controlled study.